BioInvest In The News

Top Picks 2017: Madrigal (1-20-2017)
Top Picks 2017: The Medicines Company (1-18-2017)
Top Picks 2017: Incyte (1-06-2017)
10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16)
Incyte: A Promising Pipeline (11-14-2016)
Company Updates
Esperion (ESPR)  02-20-17

Esperion (ESPR) 02-20-17

BIOINVEST BREAKING NEWS – Esperion Therapeutics (ESPR) – FDA Shows Esperion “The Way to Approval” – Raising BUY to 40 and TARGET PRICE to 60

This morning, ESPR announced that the FDA has confirmed that the bempedoic acid Phase III development program is adequate to support an approval prior to their CVOT results, lifting one of the largest overhangs on the stock, and creating a clear path to an earlier-than-expected approval.

Nektar (NKTR) 02-20-17

Nektar (NKTR) 02-20-17

BIOINVEST BREAKING NEWS – Nektar (NKTR) – NKTR-181 Successful In Phase III SUMMIT-07 Trial & Sets The Stage For A Revolution In Pain Drugs – Raising BUY and TARGET PRICE

The SUMMIT-07 trial met its primary endpoint demonstrating highly significant improved chronic back pain relief with NKTR-181 compared to placebo (p=0.0019). Moreover, the safety and tolerability of ‘181 in SUMMIT supports its breakthrough profile for moderate-to-severe pain relief without the abuse and addiction that has caused the opioid epidemic of today

The Medicines Company (MDCO) 02-17-17

The Medicines Company (MDCO) 02-17-17

BIOINVEST BREAKING NEWS – The Medicines Company (MDCO) – FOURIER IS ACTUALLY MORE POSITIVE FOR INCLISIRAN THAN BEFORE – Being the first to market is sometimes a double edged sword and is certainly the case with the Amgen’s Repatha (and REGN/SNY’s Praluent). We were at the ACC where the FOURIER* data was presented on Friday.